SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
The Maire - EuroChem Case: Three Lessons for Global Business 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
SYDNEY, Australia, May 17, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that an abstract and poster have been accepted for presentation at the American Society of Clinical Oncology (ASCO) 53rd annual meeting to be held in Chicago, Illinois, 2-6 June 2017.
The poster presentation, entitled “Combination of paclitaxel and LAG-3Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II” will be presented by lead author, Dr Francois P. Duhoux from Université Catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium.
It will provide initial safety, immune-monitoring and activity results of the 15 patient safety run-in phase of Prima’s AIPAC clinical trial for patients with hormone receptor positive (HR+) MBC combining IMP321 with first-line weekly paclitaxel.
The poster presentation will take place from 8:00am to 11:30am on Sunday, 4 June in Hall A. The shorter abstract (number 1062), just containing safety data, is available on the meeting website at http://am.asco.org/abstracts.
The full poster presentation will be available from Monday 5 June, with a link provided on the Prima BioMed website – www.primabiomed.com.au
About AIPAC (Active Immunotherapy PAClitaxel)
AIPAC is the acronym for Prima’s multicentre, Phase IIb, randomised, double-blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel. The primary purpose of the AIPAC trial is to determine the clinical benefit of IMP321 in terms of Progression-Free Survival as the primary clinical endpoint in this patient population. The study consists of two parts: a safety run-in phase (15 patients) and a randomized and controlled phase (226 patients). Details of the AIPC study are posted on www.clinicaltrials.gov (clinicaltrials.gov identifier NCT 02614833).
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected]
